Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

SELL
$21.73 - $31.43 $71,078 - $102,807
-3,271 Reduced 99.82%
6 $0
Q1 2023

May 15, 2023

BUY
$26.15 - $37.26 $85,693 - $122,101
3,277 New
3,277 $89,000
Q2 2022

Aug 15, 2022

SELL
$36.01 - $74.24 $16.1 Million - $33.1 Million
-446,179 Reduced 52.02%
411,548 $17.3 Million
Q1 2022

May 16, 2022

BUY
$60.27 - $81.57 $13.1 Million - $17.7 Million
216,531 Added 33.77%
857,727 $57.7 Million
Q4 2021

Feb 14, 2022

SELL
$65.85 - $96.21 $2.22 Million - $3.24 Million
-33,704 Reduced 4.99%
641,196 $52.7 Million
Q3 2021

Nov 15, 2021

SELL
$73.2 - $107.87 $31.1 Million - $45.8 Million
-424,700 Reduced 38.62%
674,900 $55.5 Million
Q2 2021

Aug 16, 2021

SELL
$60.45 - $84.26 $1.72 Million - $2.4 Million
-28,500 Reduced 2.53%
1,099,600 $84.7 Million
Q1 2021

May 17, 2021

BUY
$58.19 - $91.37 $36.5 Million - $57.4 Million
628,100 Added 125.62%
1,128,100 $74.6 Million
Q4 2020

Feb 16, 2021

BUY
$20.19 - $84.93 $8.82 Million - $37.1 Million
436,675 Added 689.58%
500,000 $42.5 Million
Q3 2020

Nov 16, 2020

SELL
$22.99 - $36.34 $4.93 Million - $7.79 Million
-214,294 Reduced 77.19%
63,325 $1.5 Million
Q2 2020

Aug 14, 2020

BUY
$29.88 - $56.74 $1.01 Million - $1.92 Million
33,819 Added 13.87%
277,619 $9.31 Million
Q1 2020

May 15, 2020

SELL
$33.0 - $54.5 $6.32 Million - $10.4 Million
-191,600 Reduced 44.01%
243,800 $9.83 Million
Q4 2019

Feb 14, 2020

SELL
$15.39 - $44.38 $603,241 - $1.74 Million
-39,197 Reduced 8.26%
435,400 $17.9 Million
Q3 2019

Nov 15, 2019

SELL
$21.55 - $27.61 $4.61 Million - $5.91 Million
-214,026 Reduced 31.08%
474,597 $10.2 Million
Q2 2019

Aug 14, 2019

BUY
$15.96 - $23.8 $4.37 Million - $6.51 Million
273,623 Added 65.93%
688,623 $15.1 Million
Q1 2019

May 15, 2019

BUY
$13.55 - $23.79 $5.62 Million - $9.87 Million
415,000 New
415,000 $6.13 Million

Others Institutions Holding ARVN

About ARVINAS, INC.


  • Ticker ARVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,205,300
  • Market Cap $986M
  • Description
  • Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...
More about ARVN
Track Steven Cohen's Portfolio

Track Steven Cohen Portfolio

Follow Steven Cohen (Point72 Asset Management, L.P.) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.